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Background: In the last 5 years an increasing number of studies have found that individuals who have micro-
duplications at 16p11.2 may have an increased risk of mental disorders including psychotic syndromes.
Objective:Ourmain aimwas to review all the evidence in the literature for the association between copy number
variants (CNVs) at 16p11.2 and psychosis.
Methods:We have conducted a systematic review and a meta-analysis utilising the PRISMA statement criteria.
We included all original studies (published in English) which presented data on CNVs at 16p11.2 in patients
affected by schizophrenia, schizoaffective disorder or bipolar disorder.
Results:We retrieved 15 articles which fulﬁlled our inclusion criteria. Eleven articles were subsequently selected
for a meta-analysis that showed a 10 fold increased risk of psychosis in patients with proximal 16p11.2 duplica-
tions.We conducted a secondmeta-analysis of those studieswith low risk of overlap in order to obtain the largest
possible samplewith the lowest risk of repeated results: 5 studieswere selected andwe found an odds ratio (OR)
of 14.4 (CI = 5.2–39.8; p b 0.001) for psychosis with proximal 16p11.2 duplications. The results were not signif-
icant for micro-deletions in the same region. Finally extracting only those studies that included patients with
schizophrenia we found an OR = 16.0 (CI = 5.4–47.3: p b 0.001)
Conclusions: There is a fourteen fold-increased risk of psychosis and a sixteen fold increased risk of schizophrenia
in individuals with micro-duplication at proximal 16p11.2.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
There continues to be a debate as to whether genetic inﬂuences on
schizophrenia are better explained by a “common disease-common
allele model” or a multiple rare variant model where mutations are
highly penetrant, individually rare, of recent origin and sometimes
speciﬁc to individuals or families (Walsh et al., 2008; St Clair, 2009;
Vassos et al., 2010). There has also been a growing interest in the study
of the different psychiatric conditions (such as autism, ADHD, bipolar
disorder and schizophrenia) and copy number variants (CNVs) (Kirov,
2010; Grayton et al., 2012). CNVs are micro-deletions and micro-
duplications of segments of genome ranging from a few hundred base
pairs to several megabases (Grayton et al., 2012). Genome wide screen-
ing for CNVs has become possible with the development of micro-array
based technologies, namely array comparative genomic hybridization
(aCGH) and genome wide SNP chips.
Micro-deletions at 1q21.1, 15q11.2, and 22q11.2, and micro du-
plications at 16p11.2 have been associated with an increased risk of. This is an open access article underschizophrenia (Kirov, 2010). Furthermore it appears that some of the
CNVs associated with schizophrenia have a pleiotropic effect: the same
CNV can be associated with several different clinically deﬁned con-
ditions such as epilepsy, ADHD, obesity, intellectual disability, schizo-
phrenia, bipolar disorder, autism and even normal phenotype (St Clair,
2009; van Winkel et al., 2010).
Our main aimwas to synthesize the current evidence for the asso-
ciation of CNVs at 16p11.2 (proximal and distal loci) and psychosis
(encompassing Schizophrenia, Schizoaffective Disorder and Bipolar
Disorders). Our secondary aim was to investigate the association
between schizophrenia sensu strictu and 16p11.2 CNV.2. Methods
We applied the PRISMA Statement Criteria (Liberati et al., 2009) to
our systematic search of the literature.
All primary genetic studies were included. Primary genetic studies
were deﬁned as studies where CNVs were investigated in new case
control samples, historic case control samples or a combination of both.
We also included meta-analyses of the association between CNVs atthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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participants and we did not apply any publication date restrictions.
We identiﬁed all relevant studies by searching PubMed, Web of
Knowledge and OMIM. The search was run on 13 October 2013 and
re-run again on 5 March 2014.
We used the following search terms to browse the three databases:
- PubMed, (title/abstract): {16p11.2 OR 16p11 2} AND {Schizophrenia
OR Bipolar OR Psychosis OR Schizoaffective};
- OMIM, by searching for 16p11.2 and 16p11 2;
- Web of Knowledge, by searching (topic) {16p11.2 OR 16p11 2} AND
{Schizophrenia OR Bipolar OR Psychosis OR Schizoaffective}.
The eligibility assessment was performed by GG.
We excluded studies published in languages other than English,
studies that focused on animal samples, narrative reviews, systematic
reviews, commentaries, letters to the editor, editorials, PhD theses,
book chapters and any data presented orally or in the form of posters.
We developed our own quality control grid as we could not ﬁnd any
standardized methodology applicable to psychiatric genetic studies.
GG conducted initial quality assessment of the included studies, and
afterwards NB checked the quality controlled data. Any disagreement
was resolved by discussion between the two authors and if an agree-
ment could not be reached, a third author (AM) adjudicated an outcome.
2.1. Statistical analysis
We extracted relative risks and calculated their standard errors and
conﬁdence interval. The pooled relative risk (95% conﬁdence interval)
was estimated using a ﬁxed effect model, weighting for the inverse var-
iance. Theﬁxed effect approach assumes that all the studies are estimat-
ing the same effect and only randomvariation between subjects leads to
the observed study effect to vary. This approach has been shown to beRecords idenﬁed through
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Fig. 1. Flowchart ofmore conservative compared to using a random effects model (Poole
and Greenland, 1999). We explored heterogeneity using a forest plot.
We tested for the presence of heterogeneity amongst studies using
Cochran's Q statistics where a value close to 0 indicates there is no
heterogeneity and we used I2 statistic to quantify the degree of hetero-
geneity. The I2 statistics ranges from 0% to 100% and provides ameasure
of the level of inconsistency across studies. Sensitivity analyses included
combining studies of low risk of overlapping. We also assessed the
impact of each study on the pooled estimate by omitting one study at
a time to see the extent to which inferences depended on a particular
study. We visually examined estimated effect sizes against their stan-
dard errors using funnel plots as recommended by Sterne et al. (2008)
for evidence of bias and heterogeneity. Analyses were carried out in
Stata V.13.3. Results
3.1. Study selections for the systematic review
A total of 15 studies were identiﬁed for inclusion in our review
(please see Fig. 1 for a ﬂowchart summary). The search of Web of
Knowledge, PubMed and OMIM databases provided a total of 100
citations. After adjusting for duplicates, 76 remained. After reviewing
by title and abstract 56 were discarded as they clearly did not meet
our inclusion criteria. Four articles were retrieved after hand searching
references in articles already selected and by hand searching references
in previous reviews of the literature regarding the topic. One further
article (Zheng et al., 2013) which was originally excluded due to it
being a letter to the editor was later retrieved as it communicated orig-
inal results. Therefore, a total of 25 articles were retrieved and fully
analysed with their supplements.Addional records idenﬁed
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(n = 4)
tes removed
ned Records excluded
(n =  56)
ssessed
ty
Full-text arcles excluded,
with reasons
(n =  10)
ed in
thesis
ed in
thesis
sis)
study selection.
342 G. Giaroli et al. / Schizophrenia Research 159 (2014) 340–346Of these 25 articles, one was excluded as it did not contain original
data (a). Two studies were excluded because they focused on the detec-
tion of CNVs in intellectual disability (b,c). One articlewas excluded as it
repeated data from a previous study by the same author (d). Four stud-
ieswere excluded either becausewe could not retrieve speciﬁc informa-
tion regarding the association between 16p11.2 CNV and schizophrenia
or because the data was a mixture of both historical and new data
focused on a different mental health disorder than the ones in our
search criteria (e,f,g,h). One study was excluded as it presented data
on a single nucleotide polymorphism in 16p11.2 (i). A further study
(J) was excluded as its full data set was included in the study by Guha
et al. (2013) (progressive alphabetical letters refer to supplementary
references found in supplementary material table C).
For a summary of the results of each individual study please see
Table 1 (for more details for each study please see supplementary
material text D).
3.2. Study selection for the meta-analyses, summary of results and quality
appraisal
For the meta-analysis we explored deletions and duplications at
proximal 16p11.2. 11 studies were included. The studies by Guha et al.
(2013) and Rees et al. (2014) were excluded because they focused on
a distal region of 16p11.2. The study by Ahn et al. (2014) was excluded
because the study design differed from all the others i.e. it hypothesized
a higher frequency of 16p11.2 CNVs in COS vs healthy siblings and vs
adult onset SCZ and did not therefore represent a straight forward
case control study design. Likewise the study Levinson et al. (2012)Table 1
Summary of the results for duplication and their odds (i.e. odds ratios) ratios for each individu
Study Type of study Deﬁnition of caseness N cases
Walsh et al., 2008 Prim COS 83
Prim SCZ 150
McCarthy et al., 2009 Prim SCZ 1906
Rep SCZ 2645
Comb SCZ 5877
Rep BD 3315
MA SCZ 8590
MA BD 4822
Grozeva et al., 2010 Prim BD + SCD 1697
Levinson et al., 2011 Prim SCZ + SCD 3945
MA SCZ + SCD 9890
Vacic et al., 2011 Prim SCZ 802
Rep SCZ 7488
Comb SCZ 8290
Bergen et al., 2012 Prim SCZ 1505
Prim BD 834
Van Den Bossche et al., 2012 Prim SCZ 1270
Prim BD 598
Levinson et al., 2012 Prim SCZ + SCD 1357
Grozeva et al., 2012 Hx NA NA
Hx-Comb SCZ 8590
Rep BD 7333
Szatkiewicz et al., 2013 Prim SCZ 3962
Ahn et al., 2014 Prim COS 126
Priebe et al., 2013 Prim SCZ + SCD 1637
Zheng et al., 2013 Prim SCZ 882
Rep SCZ 779
Guha et al., 2013 Prim SCZ + SCD 790
Prim SCZ + SCD 662
Rep SCZ + SCD 12,398
Rep SCZ + SCD 13,850
Rees et al, 2014 Prim SCZ 6882
Meta SCZ 16,772
Rees et al, 2014 (distal) Prim SCZ 6882
Meta SCZ 20,732
Prim = primary; Rep = replication; Comb = combination; MA = meta-analysis, Hx = his
SCD = schizoaffective disorder; PSY = psychosis; COS = childhood onset schizophrenia; NA
(i.e. odds) ratio, CI = conﬁdence interval, distal = focused on the distal portion of 16p11.2.was also excluded because their study was not a case control study,
and the Grozeva et al. (2010) study was excluded because they had fo-
cused their analysis on a healthy control group comparedwith historical
results in patients with SCZ.
In our pre-quality control meta-analysis, we utilized a ﬁxed effect
(M-H)method and found a pooledOR=10.0 (CI= 6.3–15.8; heteroge-
neity chi-squared= 13.34 (d.f. = 16); p= 0.647; I2= 0%; test of OR=
1; z = 9.87; p b 0.001) for duplication and psychosis (see Fig. 2.);
whereas for deletions we found a pooled OR = 0.736 (CI = 0.334–
1.622; heterogeneity chi-squared = 3.04 (d.f. = 5); p = 0.694; I2 =
0%; test of OR = 1; z= 0.76; p= 0.447).
Two studies (Guha et al., 2013; Rees et al., 2014) focused on CNVs in
a distal region of 16p11.2.Whilst Guha et al. showed a six fold increased
risk for SCZ and SCD for deletions, Rees et al. failed to replicate these
ﬁndings. The latter provided a combined analysis which showed an
overall OR = 3.39 (CI = 1.21–9.52; p= 0.017).
Four studies that analysed the relationship between 16p11.2 CNV
duplications and BD, only the meta-analysis of McCarthy et al. (2009)
found a statistically signiﬁcant increased risk of four times in patients
with the duplication (OR = 4.3; CI = 1.3–14.5; p= 0.017), whilst the
others failed to replicate signiﬁcant results (Grozeva et al., 2010; Bergen
et al., 2012; Rees et al., 2014).
For a summary of the quality check list and risk of overlapping of
each study please see Table 2 (also see supplementary table SA for the
methodology used to detect CNV and supplementary table SB for the
samples used in the analyses).
We deﬁned a “high quality” study as those which fulﬁlled any three
of the ﬁrst ﬁve quality criteria in the grid. If the study didn't meet theal study.
N with dup (%) N controls N dup (%) OR for dup (CI, p)
2 (2.4) 77 0 4.75 (0.2–100.6, 0.32)
0 268 0 NA
12 (0.63) 3971 1 (0.03) 25.2 (3.3–193.6, 2 × 10−5)
9 (0.34) 2420 1 (0.04) 8.3 (1.3–50.5, 0.022)
21 (0.36) 6391 2 (0.03) 14.5 (3.3–62.0, 4.3 × 10−5)
4 (0.12) NR NR NR
26 (0.30) 28,406 8 (0.03) 8.4 (2.8–25.4, 4.8 × 10−7)
6 (0.12) 25,225 7 (0.03) 4.3 (1.3–15.5, 0.017)
3 (0.18) 2806 1 (0.03) 5.0 (0.5–47.8, 0.16)
13 (0.33) 3611 1 (0.03) 11.9 (1.56–91.28, 0.003)
31 (0.31) 29,597 8 (0.03) 11.8 (35.4–25.6, 1.5 × 10−8)
4 (0.50) 742 0 8.4 (0.5–155.7, 0.15)
18 (0.24) 6689 1 (0.01) 16.1 (2.1–120.8, 0.007)
22 (0.26) 7431 1 (0.01) 19.8 (2.7–146, 0.003)
9 (0.60) 2087 1 (0.05) 12.6 (1.6–99.2, 0.02)
1 (0.12) 2087 1 (0.05) 2.5 (1.2–40.0, 0.54)
2 (016) 1145 2 (0.17) 0.9 (0.1–6.4, 0.9)
2 (0.33) 1145 2 (0.17) 1.9 (0.3–13.7, 0.51)
2 (0.15) 1104 1 (0.09) 1.63 (0.14–17.98, 0.70)
NA 10,259 4 (0.039) NA
26 (0.3) 38,665 12 (0.031) 9.8 (4.9–19.4, 1.8 × 10−15)
NA 43,779 NA 1.1 (1.0–1.1, N0.0001)
9 (0.23) 5318 1 (0.02) 11.7 (1.5–92.3, 0.02)
2 (1.59) 69 0 2.8 (0.1–59.0, 0.50)
1 (0.61) 1627 0 3.0 (0.1–73.3, 0.50)
3 (0.34) 954 0 7.6 (0.4–147.3, 0.18)
2 (0.26) 926 0 6.0 (0.3–124.3, 0.24)
0 1347 1 (0.07) NA
1 (0.15) 662 0 NA
5 (0.04) 17,945 12 (0.067) NA
6 (0.04) 19,954 13 (0.06) NA
27 (0.39) 6316 0 50.7 (3.1–inf, 2.3 × 10−8)
58 (0.35) 63,068 19 (0.03) 11.52 (6.86–19.34, 2.9 × 10−24)
0 6316 2 (0.03) NA (0–3.82,1)
13 (0.06) 27,045 5 (0.02) 3.39 (1.21–9.52, 0.017)
torical, Hx-Comb = historical combined, SCZ = schizophrenia; BD = bipolar disorder;
= not applicable; NR = not reported, Dup = duplication, Del = deletions, OR = odds
Overall  (I-squared = 0.0%, p = 0.647)
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Fig. 2. Forest plots displaying the effect of 16p11.2micro-duplications inpatientswith psychosis versus controls (pleasenote that some studies are repeated as they present different sets of
original data; the studies marked with + refer to BD). Note on case samples included (for greater detail please see Supplementary Table B): Walsh et al.(1)—original data only included;
McCarthy et al.(1)—original data (discovery sample), McCarthy et al.(2)—original data (replication sample); Grozeva, et al.—WTCCC (BD); Levinson et al.(1)—original data (MGS),
Levinson et al.(2)—meta analysis (ISC, McCarthy discovery and replication samples and MGS); Vacic et al.(1)—original data, Vacic et al.(2)—replication (MGS and ISC); Van Den Bossche
et al.(1)—original data (BD), Van Den Bossche et al.(2)—original data (SCZ); Bergen et al.(1)—original data (SCZ; Swedish register cohort and original sample), Bergen et al.(2)—original
data (BD), Zheng et al.(1)—original data (discovery sample), Zheng et al.(2)—original data (replication sample); Priebe et al.—original data; Szatkiewicz et al.—original data and Swedish
register cohort; Rees et al.—original sample (CardiffCOGS and CLOZUK); Walsh et al.(2)—original data (family sample study design therefore excluded).
343G. Giaroli et al. / Schizophrenia Research 159 (2014) 340–346aforementioned standard then it was deﬁned as “low quality”. In total,
ten of the studies met the threshold for high quality. As this quality
appraisal did not manage to screen for the risk of repeated measure
we therefore analysed only those studies which showed a low likeli-
hood of overlapping results (Walsh et al., 2008; Priebe et al., 2013;
Zheng et al., 2013; Rees et al., 2014). We also included the most recent
and largest study (Vacic et al., 2011), which despite presenting a high
risk of overlapping results actually showed a low likelihood to overlap
with the four aforementioned studies. This was done in order toTable 2
Summary of the quality grid and risk of overlapping for each study for duplication and their od
Study Description of
population
Use of standardized
measurement for diagnosis
Scr
con
Walsh et al. (2008) Yes Yes No
McCarthy et al. (2009) Yes Yes Yes
Grozeva et al. (2010) Yes Yes Yes
Levinson et al. (2011) Yes Yes Yes
Vacic et al. (2011) Yes Yes Yes
Bergen et al. (2012) Yes Yes Yes
Van Den Bossche et al. (2012) Yes Yes Yes
Levinson et al. (2012) Yes Yes Yes
Grozeva et al. (2012) Yes Yes Yes
Szatkiewicz et al. (2013) Yes Yes Yes
Ahn et al. (2014) Yes Yes Yes
Priebe et al. (2013) Yes Yes No
Zheng et al. (2013) No No No
Guha et al. (2013) Yes Yes Yes
Rees et al. (2014) Yes Yes Yesmaximize the pool of patients and controls selected with a minimum
risk of overlapping results.
Out of the 5 studies which passed our quality control measure for
low risk of overlapping we found a M-H pooled OR = 14.4 (CI = 5.2–
39.8; heterogeneity chi-squared = 2.85 (d.f. = 6); p = 0.827; I2 =
0%; test of OR = 1; z = 5.13; p b 0.001) for duplications (see Fig. 3).
The meta-analysis was then repeated focusing only on cases with
schizophrenia and therefore the study by Priebe et al. (2013) was
excluded. For this meta-analysis we found M-H pooled OR of 16.0d ratios for each individual study.
eening of
trol group
Validation
experiments
Use of historical
control
Likelihood of overlapping with
previous studies (low, high)
No No Low
Yes No High
No Yes High
Yes No High
Yes No High
Yes No High
No No High
Yes No High
Yes Yes High
Yes No High
Yes Yes Low
Yes No Low
Yes No Low
Yes No High
Yes Yes Low
Fig. 3. Forest plots displaying the effect of 16p11.2 micro-duplications in patients with psychosis versus controls after selection of low risk of overlapping studies (please note that some
studies are repeated as they present different sets of original data). Note on case samples included (for greater detail please see Supplementary Table B):Walsh et al.(1)—original data only
included; Vacic et al.(1)—original data, Vacic et al.(2)—replication (MGS and ISC); Zheng et al.(1)—original data (discovery sample), Zheng et al.(2)—original data (replication sample);
Priebe et al.—original data; Rees et al.—original sample (CardiffCOGS and CLOZUK); Walsh et al.(2)—original data (family sample study design therefore excluded).
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I-squared = 0.0%; test of OR = 1; z= 5.00 p b 0.001).4. Discussion
There is increasing interest in CNVs at 16p11.2 because of their asso-
ciation with psychosis. Of the 15 studies that we retrieved, seven had
reported signiﬁcant association between adult onset SCZ and SCD and
16p11.2 duplications, with frequencies ten times higher (ranging from
approximately 0.2% to 0.6%) in cases compared to controls (0% to
0.07%). They also found an increased risk of SCZ or SCD that was be-
tween 8 and 25 times higher in individuals with 16p11.2 duplications
(McCarthy et al., 2009; Levinson et al., 2011; Vacic et al., 2011; Bergen
et al., 2012; Szatkiewicz et al., 2013; Rees et al., 2014) (we can conﬁdent-
ly approximate the OR to the risk ratio because the disorder is rare). On
the other hand three studies which showed increased frequencies of
duplications in cases still failed to ﬁnd a statistical signiﬁcance, possibly
due to smaller datasets (VanDen Bossche et al., 2012; Priebe et al., 2013;
Zheng et al., 2013).
Walsh et al. (2008) and Ahn et al. (2014) focused their analysis on
COS; a more severe and possibly more genetically loaded form of SCZ.
Despite ﬁnding an increased frequency of duplications in cases with
SCZ compared with controls (2.4% and 0.61% respectively) than in sim-
ilar studies of adult onset SCZ, their results did not reach statistical
signiﬁcance.
The role of deletions at the distal region of 16p11.2 and psychosis is
still highly uncertain with one study ﬁnding an association and one
study that failed to replicate this ﬁnding (Guha et al., 2013; Rees et al.,
2014). Similar uncertainty is also seen in the evidence for the role of
duplications at the proximal 16p11.2 and the risk of bipolar disorder
(Grozeva et al., 2010; Bergen et al., 2012; Van Den Bossche et al., 2012).4.1. Strength of our study
To our knowledge we have been the ﬁrst to have rigorously applied
the PRISMA statement criteria to conduct a meta-analysis of the risk for
CNVs at 16p11.2 and psychosis. Furthermore, in doing so, we believe
this to be the ﬁrst study to have applied a systematic quality control
and incorporate the risk of overlapping results criteria to our meta-
analysis. Several previous publications (Levinson et al., 2011; Rees
et al., 2014) have provided original results and combined/meta-
analytical results with previous datasets; however we argue that the
choice of previous dataset appeared at times arbitrary and not support-
ed by a rigorous selection.4.2. Limitations of our study
Despite the low heterogeneity within our selected studies there are
intrinsic limitations in combining observational studies as reported by
Stroup et al. (2000).
We encountered a systematic positive results bias; in fact by utilizing
the standard search methods we have only been able to detect studies
which showed positive results either in the cases or in the controls.
Hence studies which ﬁnd no CNVs at 16p11.2 usually do not report
their analysis in their text or tables and so escaping the search engine
search. For example our own study of CNV in BD was not detected by
the search parameters utilized here (McQuillin et al., 2011). We have
however investigated though rigorous criteria all literature in different
search engines.
Finally we did not go further than searching data presented in
the original article or in the supplementary information published
in the same journal. To access the entire database was going beyond
the scope of our study; unfortunately this causes an intrinsic risk of
345G. Giaroli et al. / Schizophrenia Research 159 (2014) 340–346re-counting the same ﬁndings more than once with a risk of the over-
inﬂation of positiveﬁndings (either deletions or duplications). However,
the frequency in cases and controls is fairly consistent across studies
and large numbers have been included in the meta-analysis giving the
best possible estimate of the effect sizes of CNV at this locus in SCZ.
5. Conclusions
The concept that certain recurrent CNVs, including 16p11.2, are
important risk factors for a small proportion of patients with Schizo-
phrenia is rapidly gaining credence. A number of rare CNVs that appear
to have pleiotropic CNS effects can be considered strong susceptibility
loci for a broad range of neurodevelopmental disorders. In other
words the risk associated with these CNVs is not exclusively for schizo-
phrenia. It will be important to investigate whether healthy controls
with 16p11.2 duplications have neuropsychological intermediate phe-
notypes (Stefansson et al., 2014).
In our meta-analysis on 11 studies we robustly conﬁrmed a ten-fold
increased risk of psychotic illness in patients with proximal 16p11.2
duplications. Moreover in our “post-screening for risk of overlapping
sample” analysis we found a fourteen fold increased risk for psychosis
in patients with the duplications.
We foundno statistical association betweenmicro-deletions and psy-
chosis at proximal 16p11.2. Guha et al. (2013) and Rees et al. (2014)
were the only studies that explored in two independent samples the
distal portion of the same region, the ﬁrst ﬁnding a strong association
betweenmicro-deletions and psychosis but the other failing to observe
any deletion in 6882 cases with SCZ.
The robust association of 16p11.2 duplications and psychosis argues
for a detailed study of the duplicated region. It is important to determine
how the duplication confers this increased risk of psychosis e.g. by gene
or micro RNA dosage effect.
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